1-172660110-C-A
Variant summary
Our verdict is Benign. Variant got -9 ACMG points: 0P and 9B. BP4_StrongBP6BS2
The NM_000639.3(FASLG):c.364C>A(p.His122Asn) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000526 in 1,614,104 control chromosomes in the GnomAD database, including 1 homozygotes. In-silico tool predicts a benign outcome for this variant. 15/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_000639.3 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -9 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
FASLG | NM_000639.3 | c.364C>A | p.His122Asn | missense_variant | 2/4 | ENST00000367721.3 | NP_000630.1 | |
FASLG | NM_001302746.2 | c.348+561C>A | intron_variant | NP_001289675.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
FASLG | ENST00000367721.3 | c.364C>A | p.His122Asn | missense_variant | 2/4 | 1 | NM_000639.3 | ENSP00000356694.2 | ||
FASLG | ENST00000340030.4 | c.348+561C>A | intron_variant | 1 | ENSP00000344739.3 |
Frequencies
GnomAD3 genomes AF: 0.000329 AC: 50AN: 152200Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.000286 AC: 72AN: 251348Hom.: 0 AF XY: 0.000294 AC XY: 40AN XY: 135840
GnomAD4 exome AF: 0.000547 AC: 799AN: 1461786Hom.: 1 Cov.: 30 AF XY: 0.000520 AC XY: 378AN XY: 727194
GnomAD4 genome AF: 0.000328 AC: 50AN: 152318Hom.: 0 Cov.: 32 AF XY: 0.000309 AC XY: 23AN XY: 74486
ClinVar
Submissions by phenotype
Autoimmune lymphoproliferative syndrome type 1 Uncertain:1Benign:1
Benign, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Jan 12, 2018 | This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score and internal cut-off values, a variant classified as benign is not then subjected to further curation. The score for this variant resulted in a classification of benign for this disease. - |
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Aug 31, 2022 | This sequence change replaces histidine, which is basic and polar, with asparagine, which is neutral and polar, at codon 122 of the FASLG protein (p.His122Asn). This variant is present in population databases (rs140406512, gnomAD 0.06%). This variant has not been reported in the literature in individuals affected with FASLG-related conditions. ClinVar contains an entry for this variant (Variation ID: 293736). Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Sep 17, 2021 | The c.364C>A (p.H122N) alteration is located in exon 2 (coding exon 2) of the FASLG gene. This alteration results from a C to A substitution at nucleotide position 364, causing the histidine (H) at amino acid position 122 to be replaced by an asparagine (N). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
FASLG-related disorder Benign:1
Likely benign, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Jul 31, 2024 | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at